Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andra Balanescu

Showing results (21-30 of 51) with videos related to

Pageof 6
Sort By:
Plos One|December 14, 2017
Magnetic resonance imaging of the hand and wrist in a randomized, double-blind, multicenter, placebo-controlled trial of infliximab for rheumatoid arthritis: Comparison of dynamic contrast enhanced assessments with semi-quantitative scoringChan Beals, Richard Baumgartner, Charles Peterfy, et al.
Arthritis and Rheumatism|December 8, 2011
A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritisMichael Yellin, Igor Paliienko, Andra Balanescu, et al.
The Journal of Rheumatology|January 15, 2025
Association Between Patient Perception of Disease Status and Different Components of the Minimal Disease Activity Criteria in Psoriatic ArthritisSarah M Yazji, Philip S Helliwell, Andra Balanescu, et al.
Biomed Research International|July 2, 2014
Monitoring drug and antidrug levels: a rational approach in rheumatoid arthritis patients treated with biologic agents who experience inadequate response while being on a stable biologic treatmentDiana Mazilu, Daniela Opriş, Cecilia Gainaru, et al.
Journal of Scleroderma and Related Disorders|March 24, 2025
Interstitial lung disease in anti-U1RNP systemic sclerosis patients: A European Scleroderma Trials and Research analysisGonçalo Boleto, Corrado Campochiaro, Oliver Distler, et al.
Current Rheumatology Reviews|September 14, 2021
Do We Have Good Activity Indices in Systemic Sclerosis?Laura Groseanu, Sorana Petrescu, Andra Balanescu, et al.
Diagnostics (Basel, Switzerland)|March 27, 2024
Calcinosis in Rheumatic Disease Is Still an Unmet Need: A Retrospective Single-Center StudyCristina Nita, Laura Groseanu, Daniela Opris, et al.
RMD Open|September 14, 2023
Association between obesity and likelihood of remission or low disease activity status in psoriatic arthritis applying index-based and patient-based definitions of remission: a cross-sectional studyYing Ying Leung, Lihi Eder, Ana-Maria Orbai, et al.
Annals of the Rheumatic Diseases|April 16, 2026
Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH studyEduardo Mysler, Prodromos I Sidiropoulos, Andra Balanescu, et al.
Rheumatology (Oxford, England)|March 22, 2021
What influences patients' opinion of remission and low disease activity in psoriatic arthritis? Principal component analysis of an international studyLaura C Coates, Danielle E Robinson, Ana-Maria Orbai, et al.
Pageof 6

Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
Plos One|December 14, 2017
Magnetic resonance imaging of the hand and wrist in a randomized, double-blind, multicenter, placebo-controlled trial of infliximab for rheumatoid arthritis: Comparison of dynamic contrast enhanced assessments with semi-quantitative scoringChan Beals, Richard Baumgartner, Charles Peterfy, et al.
Arthritis and Rheumatism|December 8, 2011
A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritisMichael Yellin, Igor Paliienko, Andra Balanescu, et al.
The Journal of Rheumatology|January 15, 2025
Association Between Patient Perception of Disease Status and Different Components of the Minimal Disease Activity Criteria in Psoriatic ArthritisSarah M Yazji, Philip S Helliwell, Andra Balanescu, et al.
Biomed Research International|July 2, 2014
Monitoring drug and antidrug levels: a rational approach in rheumatoid arthritis patients treated with biologic agents who experience inadequate response while being on a stable biologic treatmentDiana Mazilu, Daniela Opriş, Cecilia Gainaru, et al.
Journal of Scleroderma and Related Disorders|March 24, 2025
Interstitial lung disease in anti-U1RNP systemic sclerosis patients: A European Scleroderma Trials and Research analysisGonçalo Boleto, Corrado Campochiaro, Oliver Distler, et al.
Current Rheumatology Reviews|September 14, 2021
Do We Have Good Activity Indices in Systemic Sclerosis?Laura Groseanu, Sorana Petrescu, Andra Balanescu, et al.
Diagnostics (Basel, Switzerland)|March 27, 2024
Calcinosis in Rheumatic Disease Is Still an Unmet Need: A Retrospective Single-Center StudyCristina Nita, Laura Groseanu, Daniela Opris, et al.
RMD Open|September 14, 2023
Association between obesity and likelihood of remission or low disease activity status in psoriatic arthritis applying index-based and patient-based definitions of remission: a cross-sectional studyYing Ying Leung, Lihi Eder, Ana-Maria Orbai, et al.
Annals of the Rheumatic Diseases|April 16, 2026
Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH studyEduardo Mysler, Prodromos I Sidiropoulos, Andra Balanescu, et al.
Rheumatology (Oxford, England)|March 22, 2021
What influences patients' opinion of remission and low disease activity in psoriatic arthritis? Principal component analysis of an international studyLaura C Coates, Danielle E Robinson, Ana-Maria Orbai, et al.
Pageof 6